BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Element Biosciences Welcomes William P. Donnelly to its Board of Directors

  Element Biosciences, Inc., developer of the Element AVITI System, an innovative DNA sequencing platform that is disrupting the genomics industry, announced that William ( Bill) P. Donnelly has joined its board of directors.

  November 21, 2023

   · 

  1 min read
• Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson

  Can-Fite BioPharma Ltd. announced that a patient who participated in the Phase II Liver Cancer Study and was treated with namodenoson has a complete response and overall survival of 6.9 years.

  November 21, 2023

   · 

  7 min read
• Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference

  Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 3:25 p.m. EST (8:25 p.m. GMT).

  November 21, 2023

   · 

  1 min read
• Kazia Provides Overview of Paxalisib Related Presentations From the Society of Neuro-Oncology 2023 Annual Meeting

  Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to provide key highlights of the clinical and preclinical paxalisib related presentations given by key thought leaders at the Society of Neuro-Oncology 2023 Annual Meeting.

  November 21, 2023

   · 

  7 min read
• Policy

  Poolbeg Pharma PLC Announces Immunomodulator II Patent Granted in Japan

  Poolbeg Pharma announces that the Japanese Patent Office has notified the Company of its official decision to grant Poolbeg’s Immunomodulator II patent application.

  November 21, 2023

   · 

  3 min read
• Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics

  Myricx Bio and WuXi Biologics announce that they have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on WuXi Bio’s integrated technology platforms.

  November 21, 2023

   · 

  4 min read
• Biovica Receives Final Pricing Decision for DiviTum TKa Test by Medicare Effective 1st January 2024

  Biovica International Biovica, active in cancer monitoring, announces that the Center for Medicare & Medicaid Services after reviewing public comments, has agreed with the minority CDLT panel to crosswalk DiviTum TKa to reimbursement code 0058U.

  November 21, 2023

   · 

  2 min read
• Business

  Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

  Greenwich LifeSciences, Inc. announced that its Board of Directors has extended the lock-up of the shares owned by the Company’s directors, officers, and existing pre-IPO investors to December 31, 2024 which is approximately 51 months from date of the Company’s IPO.

  November 21, 2023

   · 

  2 min read
• Genetown

  iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference

  iTeos Therapeutics, Inc. today announced that management will participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York City on Tuesday, November 28, 2023 at 1:30 p.m. ET.

  November 21, 2023

   · 

  1 min read